RCMT Stock Recent News
RCMT LATEST HEADLINES
PENNSAUKEN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), RCM Thermal Kinetics, a division of RCM Technologies, has announced the launch of its innovative New Ethanol eXpansion Technology (NEXT) program.
The latest trading day saw RCM Technologies, Inc. (RCMT) settling at $19.55, representing a +0.51% change from its previous close.
RCM Technologies experienced vigorous growth during COVID-19, faced setbacks in late 2022 and early 2023, but began recovering in the second half of 2023. Despite rising revenues in the third quarter, higher expenses led to lower net income; cost control is crucial for future profitability. Growth prospects are strong, driven by increased demand in healthcare, engineering, and life sciences, with analysts expecting significant earnings growth.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
RCM Technologies (RCMT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
RCM Technologies, Inc. (RCMT) concluded the recent trading session at $21.30, signifying a +1.96% move from its prior day's close.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Recently, Zacks.com users have been paying close attention to RCM Technologies (RCMT). This makes it worthwhile to examine what the stock has in store.
RCM Technologies, Inc. (RCMT) concluded the recent trading session at $20.03, signifying a -1.23% move from its prior day's close.
RCM Technologies (RCMT) is a micro-cap growth stock with rising revenue, EBITDA, and earnings, primarily from specialized healthcare staffing. Despite growing earnings, the stock price has been depressed, presenting potential for significant capital gains; Wall Street analysts predict a 67.24% increase. The company shows competitive advantages in client relationships and technical expertise, with a strong backlog and growth in various segments.